218 related articles for article (PubMed ID: 34597974)
21. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
Rinke A; Maintz C; Müller L; Weber MM; Lahner H; Pavel M; Saeger W; Houchard A; Ungewiss H; Petersenn S
Exp Clin Endocrinol Diabetes; 2021 Jul; 129(7):500-509. PubMed ID: 34293802
[TBL] [Abstract][Full Text] [Related]
22. Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):6-7. PubMed ID: 27168103
[No Abstract] [Full Text] [Related]
23. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
Ferolla P; Berruti A; Spada F; Brizzi MP; Ibrahim T; Marconcini R; Giuffrida D; Amoroso V; La Salvia A; Vaccaro V; Faggiano A; Colao A; Volante M; Ghizzoni S; Mazzanti P; Houchard A; Fazio N
Neuroendocrinology; 2023; 113(3):332-342. PubMed ID: 36044870
[TBL] [Abstract][Full Text] [Related]
25. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
Lepage C; Phelip JM; Lievre A; Le-Malicot K; Dahan L; Tougeron D; Toumpanakis C; Di-Fiore F; Lombard-Bohas C; Borbath I; Coriat R; Lecomte T; Guimbaud R; Petorin C; Legoux JL; Michel P; Scoazec JY; Smith D; Walter T
Eur J Cancer; 2022 Nov; 175():31-40. PubMed ID: 36087395
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
[TBL] [Abstract][Full Text] [Related]
27. Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms.
Laskaratos FM; Armeni E; Shah H; Megapanou M; Papantoniou D; Hayes AR; Navalkissoor S; Gnanasegaran G; von Stempel C; Phillips E; Furnace M; Kamieniarz L; Kousteni M; Luong TV; Watkins J; Mandair D; Caplin M; Toumpanakis C
Endocrine; 2020 Jan; 67(1):233-242. PubMed ID: 31556004
[TBL] [Abstract][Full Text] [Related]
28. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
Prasad V; Srirajaskanthan R; Toumpanakis C; Grana CM; Baldari S; Shah T; Lamarca A; Courbon F; Scheidhauer K; Baudin E; Truong Thanh XM; Houchard A; Dromain C; Bodei L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2358-2371. PubMed ID: 32062681
[TBL] [Abstract][Full Text] [Related]
29. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors.
Faiss S; Räth U; Mansmann U; Caird D; Clemens N; Riecken EO; Wiedenmann B
Digestion; 1999; 60(5):469-76. PubMed ID: 10473972
[TBL] [Abstract][Full Text] [Related]
30. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
Ryan P; Phan AT; Adelman DT; Iwasaki M
Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
[TBL] [Abstract][Full Text] [Related]
31. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
[TBL] [Abstract][Full Text] [Related]
32. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
[TBL] [Abstract][Full Text] [Related]
33. Lanreotide delays progression of neuroendocrine tumours.
Gilbert JA
Lancet Oncol; 2014 Sep; 15(10):e418. PubMed ID: 25328940
[No Abstract] [Full Text] [Related]
34. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Lucas T; Astorga R;
Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
[TBL] [Abstract][Full Text] [Related]
35. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
[TBL] [Abstract][Full Text] [Related]
36. PRESTO 2: An International Survey to Evaluate Patients' Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly.
O'Toole D; Kunz PL; Webb SM; Goldstein G; Khawaja S; McDonnell M; Boiziau S; Gueguen D; Houchard A; Ribeiro-Oliveira A; Prebtani A
Adv Ther; 2023 Feb; 40(2):671-690. PubMed ID: 36502449
[TBL] [Abstract][Full Text] [Related]
37. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.
Rossi RE; Invernizzi P; Mazzaferro V; Massironi S
United European Gastroenterol J; 2020 Mar; 8(2):140-147. PubMed ID: 32213066
[TBL] [Abstract][Full Text] [Related]
38. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
Chanson P; Borson-Chazot F; Kuhn JM; Blumberg J; Maisonobe P; Delemer B;
Clin Endocrinol (Oxf); 2008 Aug; 69(2):299-305. PubMed ID: 18248639
[TBL] [Abstract][Full Text] [Related]
39. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Harrow B; Fagnani F; Nevoret C; Truong-Thanh XM; de Zélicourt M; de Mestier L
Adv Ther; 2022 Apr; 39(4):1754-1771. PubMed ID: 35190997
[TBL] [Abstract][Full Text] [Related]
40. The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel.
Bianchi A; De Marinis L; Fusco A; Lugli F; Tartaglione L; Milardi D; Mormando M; Lassandro AP; Paragliola R; Rota CA; Della Casa S; Corsello SM; Brizi MG; Pontecorvi A
J Endocrinol Invest; 2011 Oct; 34(9):692-7. PubMed ID: 22067307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]